Modelling Services

Paul A. Dickinson is a prominent pharmaceutical scientist specialising in biopharmaceutics and clinical pharmacology and is the Founder and Chief Scientist of Seda. Alongside his scientific leadership, Paul has played a central role in building Seda into a successful, high‑growth consultancy, including securing growth investment from BGF and achieving recognition as an LDC Top 50 business in 2025. An internationally recognised, multidisciplinary scientist with extensive regulatory experience, Paul has contributed to the approval of many medicines and has helped shape modern, scientifically rigorous, efficient, and patient‑centric drug development practices.

‪Paul A Dickinson‬ – ‪Google Scholar‬

Linette is Chief Scientific Officer at Seda and leads the ADME Sciences Division, encompassing DMPK, clinical pharmacology, and modelling. She holds a BSc (Hons) and PhD in Chemistry from the Universities of Glasgow and Edinburgh, respectively.

With over 17 years at AstraZeneca, Linette held senior roles in Discovery and Early Pharmaceutical Development, where she provided expert input into compound design, selection, and progression. Her work focused on integrating physicochemical, ADME, and biopharmaceutics understanding using in vitro, in silico, and in vivo models to support candidate selection and early clinical development.

At Seda, Linette continues to provide strategic consultancy to clients while driving the scientific direction of the company. Her current focus is on translating ADME and pharmacodynamic insights into meaningful formulation and clinical study design to accelerate development and maximise product value.

‪Linette Ruston‬ – ‪Google Scholar‬

Jake Dickinson is a Principal Scientist and Team Leader at Seda, specialising in modelling and simulation, translational PK/PD, and physiologically based biopharmaceutics modelling. He leads Seda’s Modelling & Simulation team and has developed innovative quantitative approaches that support drug development programmes from preclinical research through to clinical and regulatory decision-making. Jake is the creator of Seda’s Nora PBBM absorption model and has worked with pharmaceutical and biotechnology companies worldwide to apply modelling strategies across a range of novel therapeutic modalities and complex parenteral formulations, accelerating development and reducing risk.

‪Jake Dickinson‬ – ‪Google Scholar‬

Harri Dickinson is an Associate Principal Scientist and Team Leader at Seda, supporting a wide range of pharmaceutical and biotechnology clients across all stages of drug development. His experience spans mechanistic PK/PD modelling, translational modelling, tumour growth inhibition modelling, clinical pharmacokinetics, and non-compartmental analysis. Harri’s core expertise is in population pharmacokinetic/pharmacodynamic (PopPK/PD) modelling and statistical exposure-response analysis, which he applies across Phase I to Phase III clinical programmes to characterise drug behaviour, understand variability, and support dose selection and optimisation.

Harri has supported programmes from first-in-human studies through to marketing application, including paediatric, rare disease, and ultra-rare disease indications where quantitative approaches are critical to development and regulatory decision-making. Despite being early in his career, he has already gained extensive experience supporting regulatory interactions and submissions with both the FDA and EMA, contributing to successful marketing applications. In addition to his technical work, Harri leads a team of modellers, driving project delivery and mentoring colleagues in quantitative clinical pharmacology.

‪Harri Dickinson‬ – ‪Google Scholar‬

Emily has a master’s degree in mechanical engineering from the University of Birmingham, where she developed a particular interest in biomedical engineering during her final year of study. Since joining Seda in 2022, she has been part of the modelling team and now works as a Senior Scientist. Her work includes pharmacokinetic (PK), pharmacokinetic/pharmacodynamic (PKPD), and population PK (PopPK) modelling, as well as non-compartmental analysis (NCA), helping clients gain a deeper understanding of their compounds and supporting drug development decision-making.